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Amiodarone-induced lung disease
To the Editor: I read the Scientific Letter by Brian Rayner,1 
concerning amiodarone-induced interstitial lung disease, with 
interest.
Interpretation of high-resolution computed tomography 
(CT) scans of the lungs, such as those obtained in this case, 
is diagnostically challenging. By way of example, ground-
glass opacification, one of the more commonly detected 
abnormalities that can be seen on high-resolution CT scanning, 
carries a differential diagnosis of more than a dozen different 
specific conditions. Interpretation is vitally dependent on 
correlating the high-resolution CT scan appearances with the 
chest radiographs and the clinical history and findings on 
clinical examination. With regard to the chest radiographs, 
review of all available previous radiographs that the patient 
might have had, as was done in this case, can provide 
important diagnostic clues. Conditions which are associated 
with interstitial fibrosis at the lung bases, such as asbestosis, 
usual interstitial pneumonia, scleroderma and rheumatoid 
lung, are commonly associated with a decrease in lung volume 
on the chest radiograph over time. The chest radiographs of 
the case presented in this instance show no reduction in lung 
volume when the current film is compared with a previous 
film, taken 10 years earlier. This could have provided a clue 
that the initial diagnosis of asbestosis should be treated 
with caution. Having said this, however, the reduction in 
lung volume is variable and not invariable. The absence of 
a decrease in lung volume is no more than a clue, but in 
the investigation of lung disease of obscure origin and the 
interpretation of high-resolution CT scans of the lungs, every 
clue is valuable.
Donald Jan Emby
AngloGold Ashanti Health
Western Deep Levels Hospital
Carletonville
demby@anglogoldashanti.com
1.  Rayner B. Clinical lesions from an elderly man with amiodarone-induced interstitial lung 
disease. S Afr Med J 2005; 97: 360-361.
Non-steroidal anti-inflammatory drugs 
and cardiovascular risk
To the Editor: Chin and Commerford1 suggest the imbalance 
between eicosanoids (prostacyclins and thromboxanes) as a 
possible cause for the observed increase in cardiovascular risk 
with the cyclo-oxygenase-2 (COX-2) inhibitors and traditional 
non-steroidal anti-inflammatory drugs (NSAIDs).1  I would 
like to suggest that the drug-drug interaction between the 
traditional NSAIDs and aspirin in post-myocardial infarction 
(MI) patients may be another contributing mechanism. 
In people who have already had an MI, aspirin is well 
known to reduce cardiovascular risk, by reducing the risk 
of further acute MI or sudden death by 25%.2 It is quickly 
absorbed from the stomach and upper small bowel, with a 
peak level about 30 minutes after ingestion. It has a short half-
life (15 - 20 minutes), being rapidly cleared by the liver.
Despite its short half-life, aspirin is able to have a profound 
clinical effect because it binds irreversibly to the COX enzymes 
of platelets. This antiplatelet effect lasts the lifespan of the 
platelet. This action on the platelet is particularly important in 
the portal system, where the concentration of aspirin is highest. 
Low-dose aspirin preferentially inhibits the COX-1 enzymes, 
compared with high-dose aspirin which inhibits both COX-1 
and COX-2 enzymes.3 
Most traditional NSAIDs also bind to the COX-1 enzyme 
on the platelets at the same site as aspirin, but in a reversible 
fashion. Therefore co-administration of NSAIDs and aspirin 
in the post-MI patient may prevent the binding of aspirin to 
the COX-1 enzyme. After the NSAIDs have disassociated from 
the platelet COX-1 enzyme, the platelet is ‘free’ to function as 
normal without the beneficial ‘anti-platelet effect’ of aspirin. 
This effect was shown in normal subjects, where single-
dose ibuprofen was administered 2 hours before aspirin. It 
was noted that the inhibition of platelet aggregation that is 
normally found with aspirin use was antagonised. This effect 
was also noted with multiple daily doses of ibuprofen, but not 
when aspirin ingestion preceded a single dose of ibuprofen.4 
(Interestingly in this study, diclofenac was not shown to affect 
the pharmacodynamics of aspirin.)
This NSAID-aspirin drug interaction could be another 
mechanism to explain the observed increase in mortality in 
post-MI patients in the Danish registry study quoted by Chin 
and Commerford.5 
Other studies have also suggested an increase in mortality 
when ibuprofen was used concomitantly with aspirin for 
secondary prevention of cardiovascular disease.6 This led 
MacDonald and Wei in their review to recommend avoiding 
chronic ibuprofen use at the same time as using aspirin for 
cardiovascular protection, especially if cardiovascular risk is 
high.7  While it is unclear whether the other NSAIDs have the 
same effect, MacDonald and Wei suggest that diclofenac at 
least may have a lesser effect. 
Brian Allwood
Medical Registrar 
Groote Schuur Hospital
Cape Town
Marc Blockman
Department of Clinical Pharmacology
University of Cape Town and
Groote Schuur Hospital
Cape Town
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Dr Chin replies: The pharmacodynamic interaction between 
the NSAIDs and aspirin is poorly understood. In the study 
by Catella-Lawson et al.,1 the concomitant administration 
of ibuprofen but not rofecoxib, paracetemol or diclofenac 
antagonised the irreversible platelet inhibition induced by 
aspirin.  Thus, in the limited evidence available, treatment with 
ibuprofen has been shown in an experimental trial to limit the 
cardioprotective effects of aspirin in patients with increased 
cardiovascular risk.1  Currently the US Food and Drug 
Administration recommends that ibuprofen be given at least 30 
minutes after aspirin or at least 8 hours before aspirin to limit 
this interaction.2  No data exist for definitive conclusions to be 
drawn about the interactions between celecoxib, indomethacin, 
other traditional NSAIDs and aspirin. Clearly the mechanism 
of cardiovascular hazard and the use of NSAIDs is 
complex.  Although limited trial evidence suggests that the 
pharmacodynamic interaction between aspirin and NSAIDs 
may be a potential mechanism, a substantial body of evidence 
indicates that suppression of COX-2-dependent prostacyclin 
formation initiates and accelerates atherogenesis.3 
1.  Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cycloxygenase inhibitors and the antiplatelet 
effects of aspirin. N Engl J Med 2001; 345: 1809-1817. 
2.  US Food and Drug Administration website. Concomitant use of ibuprofen and aspirin: 
potential for attenuation of the anti-platelet effects of aspirin. http://www.fda.gov/cder/
drug/infopage/ibuprofen/science_paper.htm (last accessed 5 December 2007).
3.  Grosser T, Fries S, FitzGerald GA.  Biological basis for the cardiovascular consequences of 
COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4-15.
Chris Barnard
To the Editor: With regard to John Terblanche’s tribute to 
Barnard in the August SAMJ,1 your readership might be 
interested in the following correspondence. 
On 3 July 2006, I wrote to the Hunterian Museums at the 
Royal College of Surgeons, Lincoln’s Inn Fields, London:
 Open Heart Surgery
 Primarily, I would like to congratulate you on your 
magnificent museums. Any person who has studied 
medicine, or has contemplated its study, or indeed has 
an interest in biological sciences, should strive for the 
privilege of a visit.
 The other purpose of this letter is as follows. In December 
2005 I enjoyed a lengthy first sojourn in the Hunterian 
Museum and noted in the Open Heart Surgery section:
 ‘In 1967 the first heart transplant was carried out’ (full stop, 
paragraph).
 A separate preceding panel, containing a photograph 
of Cooley operating, stated: ‘Denton Cooley is one of the 
pioneers of open heart surgery’ – further paragraph, then: ‘In 
1968 Cooley performed the first successful heart transplant in 
the United States and in 1969 became the first heart surgeon to 
implant an artificial heart in a human patient.’
 One was a little puzzled that no mention was made of 
the surgeon who performed the first heart transplant nor 
of where the operation took place. I thought no more of 
it at the time, but was reminded of the omission when 
I watched a short documentary on the life of Christiaan 
Barnard on the plane back to South Africa a few days 
later. Since then I have discussed both the excellence 
of the museum and this observation with friends and 
medical colleagues at home and in the UK, and have been 
surprised at the almost uniform response. Most felt that 
one had a duty to query this historical/scientific/ethical 
anomaly. 
 Therefore I paid a brief second visit to the Royal College 
of Surgeons on Wednesday 28th June 2006 to confirm my 
facts and to establish via your most helpful information 
desk the appropriate recipient of this letter.
 I look forward to your response and would be most 
grateful for comments on this small but possibly important 
issue.
 Thank you for your email. I am glad you enjoyed your 
visit to the museum. Writing text for museum displays is 
always tricky: covering a broad topic (such as post-war 
heart surgery) in fewer than 160 words is something of 
a challenge. The decision I took as Curator was to try to 
avoid mentioning individual surgeons by name – I feared 
that otherwise the panels would become simply lists of 
names and dates. The addition of the separate panel on 
Denton Cooley’s work was undertaken at the behest of our 
Trustees who felt that his overall contributions to the field 
of cardiac surgery (including, but certainly not limited 
to, his work in heart transplantation) were deserving 
of particular mention. This additional panel was added 
after the main text (with its brief reference to the 1967 
breakthrough) had been installed, otherwise I would have 
added in Barnard’s name to avoid any suggestion that 
his exclusion was in any way deliberate. Hopefully this is 
something that we will be able to correct in future, but for 
the meantime please be assured that our representation 
was not intended as any kind of slight towards Christiaan 
Barnard’s work!
Simon Chaplin, Senior Curator, replied on 6 July 2006:
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WEB-BASED CPD short courses 
 in PHARMACOLOGICAL 
 Principles of DRUG THERAPY (distance learning) 
– may lead to an Hons B Sc degree in Pharmacology
Enrol throughout the year
This unique Internet and Web-assisted learning programme has been devel oped 
by the School of Pharmacy (Faculty of Health Sciences) to give medical practitioners 
a general insight into the basic pharmacological and ethical prin ciples on which 
therapeutic strategies are based, enabling them to practise more effective pharma-
cotherapy in community medicine. 
Enrol for the whole programme or selected modules only.
Who should enrol?
• Medical Practitioners and Specialists
• Pharmacists
Why enrol?
• Continued Professional Development (CPD) 
• Stay abreast with the latest trends in Pharmacology
• Empowerment for career development
Candidates can either enrol for the degree programme or specific 
module(s) as certificate course(s).
Some of the certificate courses on offer for you:
• Drugs and the Peripheral Nervous System
• Drugs and the Central Nervous System
• Drugs and the Renal and Cardiovascular Systems
• Drugs for Pain, Inflammation, Fever and Airways Disease 
• Chemotherapy of Infections and Infestations
• Hormones, Hormonoids and Hormone Antagonists Drugs 
for GIT and Skin
• Vitamins, Haematopoietics and Immunopharmacology
• Advanced Pharmacological Principles
• Evidence-Based Medicine
Please visit our website at: 
www.nwu.ac.za/webpharmacol for more information 
or contact: Alsorika Kraukamp  
Tel: +27(0)18 299 2260 Fax: +27(0)18 299 4244
E-mail: alsorika.kraukamp@nwu.ac.za
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